文献速递关节外科

无菌性翻修全膝关节置换术中骨内注射万古霉素后假体周围关节感染风险低

Low Risk of Periprosthetic Joint Infection After Aseptic Revision Total Knee Arthroplasty With Intraosseous Vancomycin.
PubMed 文献 · J Arthroplasty · 2024-05-23

本研究连续纳入117例2016年1月至2022年3月由2名成人关节重建专科医生实施的无菌性翻修全膝关节置换术病例,术中在标准静脉抗生素预防基础上加用骨内注射万古霉素。术后3个月假体周围关节感染率为0%,1年时仍为0%,最终随访(≥1年)感染率为0.88%(95%CI:-0.84至2.61),作者认为该方案与既往文献报告的3%至9.4%相比可大幅降低早期假体周围关节感染。

要点

  • 无菌性翻修全膝关节置换术中加用骨内注射万古霉素,术后3个月假体周围关节感染率为0%。
  • 术后1年假体周围关节感染率仍为0%,最终随访(≥1年)感染率为0.88%(95%CI:-0.84至2.61)。
  • 作者认为骨内注射万古霉素联合静脉头孢菌素或克林霉素与既往文献相比可大幅降低早期假体周围关节感染。

核心结论

  • 无菌性翻修全膝关节置换术中采用骨内注射万古霉素联合静脉头孢菌素或克林霉素的双重预防抗生素方案,与既往发表文献相比与早期假体周围关节感染大幅降低相关。
  • 这些数据补充了关于骨内注射万古霉素在高风险病例中预防感染的潜在临床益处的早期证据。

研究设计与样本

  • 连续纳入117例于2016年1月至2022年3月期间由2名接受过专科培训的成人关节重建外科医生之一实施的无菌性翻修全膝关节置换术病例。
  • 所有病例术中除标准静脉抗生素预防外,均接受骨内注射万古霉素。
  • 评估术后3个月、1年及最终随访时的假体周围关节感染率,并与既往文献进行比较。
  • 证据等级为III级,治疗性研究。

主要发现

  • 117例翻修全膝关节置换术中,116例获得术后3个月随访,1例失访;术后3个月假体周围关节感染率为0%。
  • 117例中113例获得术后1年随访,假体周围关节感染率仍为0%。
  • 最终随访≥1年时假体周围关节感染率为0.88%(95%置信区间:-0.84至2.61)。
  • 既往文献报告无菌性翻修全膝关节置换术后假体周围关节感染率为3%至9.4%。

关键数值与推荐

  • 术后3个月假体周围关节感染率为0%(116/117例获得随访)。
  • 术后1年假体周围关节感染率为0%(113/117例获得随访)。
  • 最终随访≥1年时假体周围关节感染率为0.88%(95%置信区间:-0.84至2.61)。

临床怎么用

  • 作者认为骨内注射万古霉素联合静脉头孢菌素或克林霉素的双重预防抗生素方案与既往文献相比与早期假体周围关节感染大幅降低相关。
  • 作者认为这些数据补充了骨内注射万古霉素在高风险病例中预防感染的潜在临床益处的早期证据。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Aseptic revisions are the most common reason for revision total knee arthroplasty (rTKA). Previous literature reports early periprosthetic joint infection (PJI) rates after aseptic rTKA to range from 3 to 9.4%. Intraosseous (IO) regional administration of vancomycin has previously been shown to produce high local tissue concentrations in primary and rTKA. However, no data exist on the effect of prophylactic IO vancomycin on early PJI rates in the setting of aseptic rTKA. The aim of this study was to determine the following: (1) what is the rate of early PJI during the first year after surgery in aseptic rTKA performed with IO vancomycin; and (2) how does this compare to previously published PJI rates after rTKA. METHODS: A consecutive series of 117 cases were included in this study who underwent rTKA between January 2016 and March 2022 by 1 of 2 fellowship-trained adult reconstruction surgeons and received IO vancomycin at the time of surgery in addition to standard intravenous antibiotic prophylaxis. Rates of PJI at 3 months, 1 year, and the final follow-up were evaluated and compared to prior literature. RESULTS: Follow-up at 3 months was available for 116 of the 117 rTKAs, with 1 lost to follow-up. The rate of PJI was 0% at 3 months postoperatively. Follow-up at 1 year was obtained for 113 of the 117 rTKAs, and the PJI rate remained 0%. The rate of PJI at the final follow-up of ≥ 1 year was 0.88% (95% confidence interval: -0.84 to 2.61). Previous literature reports PJI rates in aseptic rTKA to range from 3 to 9.4%. CONCLUSIONS: Dual prophylactic antibiotics with IO vancomycin in conjunction with intravenous cephalosporins or clindamycin were associated with a substantial reduction in early PJI compared to prior published literature. These data supplement the early evidence about the potential clinical benefits of IO vancomycin for infection prevention in high-risk cases. LEVEL OF EVIDENCE: Level III, therapeutic study.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Christopher ZK, Pulicherla N, Iturregui JM, et al. Low Risk of Periprosthetic Joint Infection After Aseptic Revision Total Knee Arthroplasty With Intraosseous Vancomycin. J Arthroplasty. 2024. PMID: 38795854. doi:10.1016/j.arth.2024.05.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。